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Abstract: Twenty-five years has now passed since variant Creutzfeldt-Jakob disease (vCJD) was first
described in the United Kingdom (UK). Early epidemiological, neuropathological and biochemical
investigations suggested that vCJD represented a new zoonotic form of human prion disease resulting
from dietary exposure to the bovine spongiform encephalopathy (BSE) agent. This hypothesis
has since been confirmed though a large body of experimental evidence, predominantly using
animal models of the disease. Today, the clinical, pathological and biochemical phenotype of
vCJD is well characterized and demonstrates a unique and remarkably consistent pattern between
individual cases when compared to other human prion diseases. While the numbers of vCJD cases
remain reassuringly low, with 178 primary vCJD cases reported in the UK and a further 54 reported
worldwide, concerns remain over the possible appearance of new vCJD cases in other genetic cohorts
and the numbers of asymptomatic individuals in the population harboring vCJD infectivity. This
review will provide a historical perspective on vCJD, examining the origins of this acquired prion
disease and its association with BSE. We will investigate the epidemiology of the disease along with
the unique clinicopathological and biochemical phenotype associated with vCJD cases. Additionally,
this review will examine the impact vCJD has had on public health in the UK and the ongoing
concerns raised by this rare group of disorders.
Keywords: variant Creutzfeldt-Jakob disease; prion diseases; BSE; transmission; blood transfu-
sion; prevalence
1. Introduction
Prion diseases or transmissible spongiform encephalopathies (TSEs) are a group of
rare neurodegenerative conditions that occur naturally in humans as well as a range
of animal species. Human prion diseases share many clinical and neuropathological
features with that of more common neurodegenerative conditions such as Alzheimer’s
disease and Parkinson’s disease, in particular the accumulation in the brain of abnormal,
disease-specific protein aggregates [1]. In prion diseases, this protein is a misfolded and
partially protease-resistant form of a normal host-encoded cellular protein, the prion
protein (PrPC) [2–4]. Consistent with most neurodegenerative conditions, prion diseases
can occur in both sporadic and genetic forms; indeed, sporadic Creutzfeldt-Jakob disease
(sCJD) is the most common form of human prion disease, accounting for approximately
85% of all human prion diseases [5]. However, a unique feature of prion disease, and one
that continues to set them apart from all other neurodegenerative conditions, is that they
may also be acquired, with the ability to transmit infectivity between individuals of the
same species and in some instances between different species [6]. As a consequence of
this infectious nature, prion diseases represent a neurodegenerative condition that poses a
serious public health concern.
In 1996, a new form of acquired human prion disease was identified in the United
Kingdom (UK). Initially referred to as “new variant” CJD (nvCJD) and since shortened to
variant CJD (vCJD) [7], this condition would propel this rare group of neurodegenerative
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disorders to the forefront of the scientific community and would have an unprecedented
and lasting impact on public health in the UK. Twenty-five years on from the first iden-
tification of vCJD, this review will provide a historical perspective of this unique form
of acquired human prion disease—from its origins and first recognition in humans, to
current diagnosis and epidemiology of the disease. Additionally, we will detail the public
health impact following the identification of vCJD in the UK and the current public health
concerns that still surround this condition a quarter of a century on.
2. The Emergence of vCJD
The first cases of vCJD were reported in the UK in 1996 (Figure 1) [7]. However,
the origins of this human prion disease date back approximately ten years earlier to the
emergence of bovine spongiform encephalopathy (BSE) in the UK, a novel prion disease
affecting cattle [8]. From its first identification in 1985 (Figure 1), annual numbers of
BSE cases in cattle increased rapidly in the UK, reaching a peak in 1992 with more than
37,000 cases recorded (Figure 1) [9]. Subsequently, cases of BSE have been identified in
an additional 25 countries, predominantly in Europe, Asia, the Middle East and North
America [10]. While the original source of BSE is yet to be clearly established, the epidemic
of BSE in cattle has been attributed to the recycling of prion contaminated carcasses (such as
sheep with scrapie or a sporadic case of cattle BSE) in the manufacturing of cattle feed in the
form of meat and bone meal (MBM) [11,12]. On the other hand, subsequent transmission
of atypical forms of BSE in cattle [13–15] and scrapie in sheep [16] into transgenic mouse
models over-expressing bovine PrP induce strain features similar to that of classical BSE.
Figure 1. Timeline of the last 35 years highlighting significant dates in the origin, emergence and progression of vCJD. Time
points in grey correspond to Western blot images presented in Figure 4d.
From 1988, a number of rigorous control measures were implemented in the UK (and
subsequently emulated in some other countries) including (i) the introduction of a ban
on the supply and use of ruminant-derived protein in ruminant feed, (ii) the compulsory
slaughter and disposal of remains of all cattle suspected of having BSE, (iii) a ban on
the feeding of specified bovine offal to humans and farmed animals, (iv) the targeted
surveillance and mandatory reporting of clinical neurological disease in cattle, and (v) the
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removal of cattle over 30 months from the food chain [11,12]. As a result, numbers of BSE
cases in the UK declined rapidly, and today BSE is considered a rare disease with only a
single case recorded in the UK over the last five years [9]. It is worth noting that the steady
decline in BSE cases has led to a relaxation of some of these measures over the last number
of years [17].
Inevitably, the emergence of the BSE epidemic in the UK raised public health concerns
over the potential cross-species transmission of BSE to humans through dietary exposure
to the BSE agent through contaminated food products. These concerns were heightened
following parallel reports of a similar spongiform encephalopathy in domestic and captive
cat species (now referred to as feline spongiform encephalopathy) and in some species
of captive exotic ungulates [18–21]. The possibility that prion disease in these animals
had resulted by the cross-species transmission of BSE through food supplements was
thought the most likely cause. In response to these concerns, the UK government reinstated
epidemiological surveillance and research into Creutzfeldt-Jakob disease (CJD) in May
1990 (Figure 1) in order to monitor and identify any changes in the incidence or pattern of
CJD in the wake of the BSE epidemic [22]. This expansion in surveillance was emulated in
a number of other European countries, and following the identification of vCJD in the UK,
it was established in other non-European countries as well [23–28].
In 1996, a seminal report by Robert Will and colleagues described 10 cases of CJD
identified in UK patients of an unusually young age (median 29 years, while sporadic
CJD primarily affects individuals over the age of 60) [7]. These 10 patients presented with
atypical clinical symptoms and a highly consistent neuropathological phenotype that had
not previously been recognised in any other forms of human prion disease. Furthermore,
the disease duration was much longer than that observed in patients diagnosed with the
more commonly occurring sporadic CJD (sCJD). An alternative diagnosis of iatrogenic
CJD (iCJD) was thought unlikely in these patients because investigation of the clinical
histories found no evidence of potential iatrogenic exposure to CJD through either dura
mater grafting, a history of childhood treatment with pituitary derived growth hormone,
neurosurgery or blood transfusion. In addition, genetic sequencing on eight of the 10 cases
found no mutations in the prion protein gene (PRNP) that is associated with the inherited
forms of prion disease. Will and colleagues concluded that these 10 cases represented a new
clinicopathological variant of CJD and, having occurred so soon after the BSE epidemic,
and with cases exclusively found in the UK (where the BSE epidemic was at its most severe),
the most “plausible interpretation” of the findings was that these cases were a direct result
of human exposure to the BSE agent [7]. In March 1995, these findings were reported to the
UK government by the Spongiform Encephalopathy Advisory Committee (SEAC) of the
Department of Health (DOH) and Ministry of Agriculture, Fisheries and Food (MAFF). In
addition to public concern over the emergence of this new acquired form of prion disease,
the identification of vCJD led to a worldwide ban on the export of British beef causing a
severe economic impact in the UK beef industry [29]. Like several other control measures
implemented in the wake of the BSE epidemic, the ban posed on the exportation of British
beef has since been lifted in Europe, and more recently in the United states [30,31].
3. BSE and vCJD, A Single Strain of Agent
A large body of evidence now exists supporting the hypothesis that vCJD has resulted
from human infection with the BSE agent. In addition to epidemiological arguments, the
most compelling evidence has come from experimental animal models and from analysis
of the biochemical phenotype of the misfolded and disease-associated form of the prion
protein (PrPSc) that accumulates in the brain and peripheral tissues of vCJD patients. A
notable feature of the zoonotic transmission of BSE to other species is the maintenance of its
distinctive molecular signature [32]. However, animal transmission studies have recently
highlighted the concern that cross-transmission of BSE to sheep or goats may result in a
subtle adaptation of BSE, resulting in increased virulence towards humans [33,34].
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3.1. Animal Models of vCJD
In the same year that vCJD was first described in the UK, results from the intrac-
erebral inoculation of brain isolates from BSE-infected cattle in cynomologus macaques
demonstrated that BSE was highly infectious in this primate model [35]. Examination of
brain tissue at post-mortem revealed a pattern of pathology in the macaques that was
indistinguishable to that observed in vCJD patients, but which differed to that obtained
with sCJD in the same primate model [35].
Shortly after this report, a seminal study by Moira Bruce and colleagues published
the interim results from the first experimental inoculation of vCJD brain isolates in inbred
strains of wild-type mice [36]. These wild-type mouse lines (RIII, VM and C57BL), which
carry different alleles of the mouse PrP gene (Prn-p), are a mainstay in prion research, able
to discriminate between different prion “strains” based on their unique biological proper-
ties on serial passage, specifically by incubation periods and patterns of neuropathological
targeting, known as the “lesion profile” [37–41]. Experimental transmission studies carried
out during the peak of the BSE epidemic demonstrated a single unique strain “signature”
associated with cattle BSE when passaged in these mouse lines [42,43]. Remarkably, this
corresponding BSE signature was also observed following transmission of infected brain
tissue from other animal species, including domestic cats, greater kudu and Nyala, con-
firming that the same single strain of agent was responsible for these other animal prion
diseases [44,45]. In the study performed by Bruce and colleagues, intracerebral inoculation
of brain isolate from three vCJD patients in wild-type mice resulted in transmission proper-
ties (incubation period and lesion profile) that were indistinguishable from that of cattle
BSE and other BSE-related prion disorders [36]. Crucially, the strain signature differed
from the diseased-associated pattern obtained with sCJD brain isolates passaged in the
same mouse lines. While the published data was based on interim results from a single
mouse strain (RIII), this was considered as a strong indication that the same strain of agent
was involved in BSE and in vCJD, and that BSE presented a possible zoonotic risk resulting
in vCJD. The complete data set from these three primary transmissions, including immuno-
histochemical and biochemical analysis of PrPSc in the brain and subsequent secondary
passages, was published several years later, alongside transmission data from an additional
seven vCJD patients [46,47]. With the same BSE signature observed in all transmission
experiments, this information was taken as convincing evidence that vCJD was a result
of human infection with the BSE agent. The studies by Bruce and colleagues have been
further supported by a wealth of experimental transmission studies in both wild-type and
transgenic mouse models that appear to confirm that BSE in cattle and vCJD in humans are
caused by a single agent strain [48–50].
In addition to confirming an association with exposure to BSE, animal models have
been instrumental over the last 25 years in contributing to our understanding of many
other biological aspects of vCJD. Transgenic mouse models have been fundamental in
establishing the influence of the naturally occurring methionine (M)/valine (V) polymor-
phism at codon 129 of PRNP on the susceptibility to vCJD [51–54]. Similarly, wild-type
mouse models have highlighted the different pathogenesis in vCJD when compared to
other prion diseases, with infectivity detected in lymphoreticular tissues [47,55]. Sub-
sequent studies in both wild-type and transgenic mice demonstrated that infectivity in
lymphoreticular tissues may occur in vCJD patients prior to neuroinvasion and the onset
of disease [56]. Such properties continue to have a significant impact on public health
concerns and the implementation of public health policies. Furthermore, these same mouse
studies have confirmed that the BSE/vCJD strain is not generally altered by the tissue of
origin [47,55,56], the PRNP codon 129 genotype of the individual [56–58], geographical
location [59,60], age [60] or following secondary human transmission of vCJD through
blood transfusion [56,61].
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3.2. Biochemical Properties of PrPSc in vCJD
In the absence of any identifiable nucleic acid associated with prion diseases, the
phenomenon of prion strains is thought to be enciphered by conformational variability in
PrPSc, the misfolded and disease-associated form of the prion protein that accumulates
in the brain (and peripheral tissues in vCJD) [62–69]. Such variabilities are commonly
measured by examining the molecular weight (N-terminal truncation of the protein) and
glycosylation profile (occupancy of the two asparagine-linked glycosylation sites) of PrPSc
after limited proteolytic digestion (PrPres) using Western blot analysis [32,63,68]. In the
initial analysis of PrPres from brain tissue of vCJD patients, two separate studies, led by
John Collinge and Piero Parchi, respectively, described a distinct and consistent PrPres
profile that had not been commonly observed in any form of human prion disease, apart
from some familial cases [32,69]. This PrPres, termed type 2B (Parchi classification) [69] or
type 4 (Collinge/London classification) [32] is characterised by an unglycosylated fragment
size of ~19 kDa and a marked predominance in the diglycosylated fragment of PrPres. This
PrPres profile is identical to the molecular signature for BSE in cattle and to that of naturally
transmitted BSE in domestic cats, and in BSE experimentally transmitted to wild-type mice
and macaques, further supporting a causal association between BSE and vCJD [32].
4. Epidemiology
4.1. Primary Cases of vCJD
As of July 2021, twenty-five years from the first descriptions of vCJD in the UK, 232
clinical cases of definite or probable vCJD have been reported worldwide, in individuals
from 12 countries, including the UK (178 cases), France (28 cases), Spain (5 cases), Republic
of Ireland (4 cases), U.S.A (4 cases), Italy (3 cases), Netherlands (3 cases), Portugal (2 cases),
Canada (2 cases), Taiwan (1 case), Saudia Arabia (1 case) and Japan (1 case) [70]. With
vCJD causally linked to the BSE epizootic, it is perhaps unsurprising that the majority
of vCJD cases have occurred in the UK where the BSE epidemic was most severe. In
non-UK countries, the presence of vCJD has been associated with exposure to the BSE
agent through (i) indigenous cases of BSE in cattle within the country of residence [10,71],
(ii) UK residency during the period when BSE exposure was at its highest levels [72–77], or
(iii) through importation of contaminated beef products from the UK [75,78,79].
Cases of vCJD have declined over the last two decades, having reached a peak in 2000
with 29 recorded deaths (28 in the UK and 1 in France) [70]. The last known UK case of
vCJD was reported in 2016 with a clinical onset in 2014 [80]. In non-UK vCJD cases, the last
case was reported in France in 2019 with the patient having an onset in 2017 (Figure 1) [81].
While dietary exposure to the BSE agent is recognised as the prevailing cause of vCJD
cases [82], the last recorded case of vCJD has been associated with possible occupational
exposure (i.e., a laboratory accident) [81,83].
Of the 232 vCJD cases who have undergone full genetic analysis, all but a single
case has occurred in individuals homozygous for methionine (MM) at codon 129 on
PRNP, a recognised risk factor for human prion diseases. The remaining vCJD case, and
the last reported in the UK, was the first pathologically confirmed case of vCJD in a
methionine/valine (MV) heterozygote patient [84]. A suspected case of vCJD in a MV
heterozygote had been described in 2009 [85]; however, in the absence of a post-mortem, a
diagnosis of vCJD was not confirmed. The identification of vCJD in a PRNP codon 129 MV
individual was not unexpected because earlier experimental evidence from humanised
transgenic mouse models, expressing physiological levels of the human prion protein,
indicated that other PRNP codon 129 genotypes are susceptible to infection with the BSE
agent but may be subject to more prolonged incubation periods [53]. In addition, in vitro
amplification experiments using human post-mortem tissue from patients who died from
non-neurological conditions and humanised transgenic mouse brains had shown that
normal cellular prion protein (PrPC) from MV individuals could be converted by MM vCJD
PrPSc, albeit with decreased efficiency [86]. While the pathological and biochemical features
of vCJD in the MV individual were indistinguishable from that of vCJD in MM individuals,
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the clinical features were more consistent with those described in sCJD patients [84]. This
has raised the possibility that any future cases of vCJD occurring in PRNP codon 129
genotypes other than MM may be more difficult to identify based on clinical presentation.
This highlights the importance of continued surveillance of human prion diseases in the
UK, involving the post-mortem examination of patients [83]. Experimental transmission of
brain isolates from the case of vCJD in a MV individual, into a wild-type mouse model,
provided evidence that strain properties were identical to those observed for the agent
associated with vCJD MM individuals [58]. This observation was consistent with the views
that a single unique strain of agent was involved with BSE and vCJD, and it suggests that
there is no adaption of this strain in a different genetic background.
4.2. Secondary Human-to-Human Transmission of vCJD in the UK
While there is no epidemiological evidence to suggest that sCJD is transmissible via
blood transfusion [87,88], the greater extent of peripheral pathogenesis, particularly in
lymphoreticular tissues, in vCJD cases [89–92], raised concerns that vCJD poses a greater
risk for iatrogenic secondary transmission, potentially via surgery or blood transfusion.
This fear was supported by animal studies demonstrating that BSE in experimentally-
infected sheep could be successfully transmitted via transfusion with blood collected
during the clinical and the asymptomatic phase of the disease [93–95]. In response, and
with an increasing number of vCJD cases, a look back study, the Transfusion Medicine
Epidemiology Review (TMER), was established in 1997 to look for any evidence that CJD
may have transmitted via the UK blood supply.
The above concerns were justified in 2003 with the occurrence of the first case of vCJD
following blood transfusion from a donor who later developed vCJD (Figure 1) [96]. Subse-
quently two further clinical cases of vCJD following blood transfusion were reported [97,98].
All three clinical cases of vCJD following blood transfusion were MM at PRNP codon 129.
In 2004, a case of preclinical vCJD infection following blood transfusion was reported [99].
Post-mortem examination of this case showed evidence of vCJD PrPSc deposition in the
spleen and cervical lymph node but not in the brain. The patient had died from a condi-
tion unrelated to prion disease, five years following blood transfusion from an infected
donor [99]. In contrast to the clinical transfusion transmitted vCJD cases, the preclinical
case was MV at PRNP codon 129. While it is unknown whether they would have gone on
to develop vCJD, this was the first demonstration that vCJD infection could replicate in an
MV individual. Subsequently, infectivity in the spleen from this case has been confirmed by
bioassay [56]. The strain characteristics matched those previously described for vCJD/BSE,
demonstrating that replication in lymphoreticular tissue, and in a PRNP codon 129 MV
genetic background, do not affect the characteristics of the vCJD strain. All four blood
transfusion cases suggest that there is sufficient infectivity in blood at a presymptomatic
stage to cause infection in another individual. Figure 2 shows that the incubation periods
between transfusion and the onset of clinical symptoms varied from 6.5 to 8.5 years. This is
broadly in line with incubation period for vCJD estimated from the lag between the peaks
of the BSE and vCJD epidemics [100–102]. Shown as well is the time interval between the
donation of blood and the onset of symptoms in the donor (Figure 2). This is indicative
that the vCJD-infected donors potentially may harbour significant infectivity in their blood
at least 1.4–3.3 years prior to the appearance of vCJD symptoms.
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Figure 2. Pre-symptomatic phases for donors and recipients of vCJD-infected blood. Comparison of
the lengths of the pre-symptomatic phase of vCJD patients who had received blood from infected
donors. For the four cases of vCJD infection following blood transfusion (including a preclinical
case), the time elapsed between receiving the blood transfusion (red circles) and the onset of clinical
symptoms (or death) is indicated. The time after the donation when clinical onset occurred in the
donor is also indicated (orange hexagon).
Each of the four-blood transfusion associated vCJD infections occurred in recipients
of non-leucoreduced blood, prior to leucodepletion of all blood components in the UK that
was brought into effect in 1999. The TMER study identified 67 individuals who received
blood components from vCJD donors, and it is encouraging that there have been no further
cases of vCJD following blood transfusion, suggesting that leucodepletion was an effective
countermeasure [97,103]. However, animal model experiments demonstrated that all
blood components could potentially transmit disease, suggesting a need for continued
surveillance for blood transfusion-associated vCJD [104].
Studies of blood donor and recipient pairs suggest that we should not expect any
change in the clinical and pathological profile or agent strain as a result of secondary
transmission [61,103,105]. However, it needs to be borne in mind that future cases of
vCJD following blood transfusion would most likely occur in older individuals as the
risk of requiring a transfusion increases with age [106]. In addition, some models of
vCJD blood transmission, using both mice and macaques, have identified a different class
of neurological impairment. It was demonstrated that these impairments had a prion
aetiology but notably lacked classic neuropathological features of prion disease, including
deposition of PrPSc [107]. This suggests the scope of surveillance may need to widen to
include neurological conditions that do not fit the current criteria for prion disease and
where protease-resistant PrP is absent.
In addition to blood components, another potential means for secondary transmission
is human plasma derived medical products. In 1999, a ban on the use of UK sourced
plasma for manufacturing blood products that was imposed to prevent secondary vCJD
transmission. However, active tissue-based surveillance of patients who had received blood
products, identified evidence of vCJD infection in a haemophiliac patient who, many years
prior to the aforementioned ban, had received treatment with factor VIII concentrate [108].
Batches of factor VIII concentrate had been prepared by pooling large numbers of UK
human plasma donations. Some of the batches received by the patient in question were
subsequently found to have been derived from plasma pools that included a donation
from a vCJD-infected donor. This haemophiliac patient, who was MV at PRNP codon
129, died from causes unrelated to CJD, but PrPSc was detected in their spleen, suggesting
they may have acquired the vCJD prion agent as a result of factor VIII therapy. This same
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study found no evidence of vCJD infection in autopsy or biopsy material from 16 other
haemophiliac patients who had received plasma-derived factor VIII [108]. It should be
noted that the ban on the use of UK sourced plasma for blood products was subsequently
lifted in 2019 following a report that revised down the risks of future vCJD cases arising
through treatment with plasma products [109].
The risk of future clinical cases of secondary transmission vCJD depends on the
prevalence of subclinical vCJD in the population and likelihood that subclinical carriers
will go onto develop vCJD. The risk of secondary transmission via blood or blood products
could be assessed with a rapid and highly sensitive assay that could be used to screen
donations. No such assay has yet been fully developed or validated, but several scientific
reports have proven the principle that vCJD PrPSc could be directly captured and detected
in blood with a sensitivity of around 70% and very high specificity [110,111].
More recently, developments in the use of in vitro conversion assays, specifically the
protein misfolding cyclic amplification (PMCA) assay, have proven sufficiently powerful
to amplify and detect PrPSc in blood or plasma from vCJD patients at both clinical and
preclinical stages with near 100% specificity and sensitivity [112–115]. Similar to PMCA,
the real-time quaking-induced conversion (RT-QuIC) assay is another powerful method
based on amplifying misfolded PrP [116,117]. RT-QuIC analysis of cerebrospinal fluid is
now an important tool for ante-mortem diagnosis and surveillance for sCJD. However,
technical challenges remain, specifically with RT-QuIC’s ability to detect vCJD PrPSc and
PrPSc in blood [118–121].
5. Diagnosis
In line with other human prion diseases, internationally agreed diagnostic criteria is
available for the diagnosis of vCJD which categorise cases as either “definite”, “probable”
or “possible” (Figure 3) [122]. These criteria are based on the acquisition and assessment of
clinical, histological, immunohistochemical, biochemical and genetic investigations and
has proven highly sensitive and specific in the classification of vCJD cases [123].
5.1. Clinical Features
In contrast to other forms of prion disease, vCJD affects individuals of an unusually
young age, predominantly in the third decade of life. The youngest vCJD patient, one of
two cases reported in Portugal, had a clinical onset of 11 years [124]. The oldest patient had
an onset of 74 years; one of only six vCJD patients reported having a disease onset over the
age of 55 years [80]. The prevalence of vCJD in this young age distribution is thought to be
attributed to age-related differences in either dietary exposure to the BSE agent [125] or in
disease susceptibility [126]. Mean duration of illness is approximately 14 months, much
longer than the 4 months reported in sCJD cases [80].
The clinical symptoms of vCJD are relatively uniform, predominantly presenting with psy-
chiatric features such as anxiety, withdrawal, depression and personality change [123,127,128].
As a consequence, there are several early accounts of patients having been referred to psychiatric
services in the first instance [128]. Psychiatric features may present on their own but can be
accompanied by a range of sensory abnormalities that include limb pain and parasthesiae [129].
Neurological signs of disease, typically develop around six months and include; progressive
ataxia, visual problems, cognitive decline and involuntary movements including myoclonus,
dystonia and chorea [130]. The end stage of disease is similar to that observed in sCJD patients,
with terminal akinetic mutism in many cases.
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Figure 3. Diagnostic criteria for variant Creutzfeldt-Jakob disease. Adapted from http://www.cjd.
ed.ac.uk/sites/default/files/criteria_0.pdf [122] (accessed on 1 July 2021).
There are a number of additional clinical investigations that have proven valuable in
supporting a diagnosis of vCJD and, crucially, in excluding potential treatable conditions.
One of the most useful is the magnetic resonance imaging (MRI) brain scan, which produces
a distinctive high signal on T2 and fluid-associated inversion recovery (Flair) sequence
in the posterior thalamus in vCJD patients. Referred to as the “pulvinar sign”, this forms
part of the diagnostic criteria for a possible and probable diagnosis for vCJD, having been
observed in over 90% of cases examined (Figure 3) [122,131]. The electroencephalogram
(EEG), cerebral spinal fluid (CSF) 14-3-3 assay and RT-QuIC assay, which have proven
helpful in the diagnosis of sCJD [132–134], are less useful in suspected cases of vCJD. The
periodic sharp wave complexes that are characteristic of the EEG in sCJD patients are not a
feature in vCJD patients; however, there are some rare reports that these feature in the later
stages of the disease (Figure 3) [73,135]. Analysis of CSF 14-3-3 levels shows positivity in
only 50% of vCJD cases, compared to around 90% of sCJD cases. However, elevated levels
of phospho-tau in the CSF have been reported in many cases of vCJD [136].
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5.2. Neuropathology
In vCJD, as in all forms of prion disease, neuropathological examination is a require-
ment for a definite diagnosis. Brain biopsy may be performed in patients where a diagnosis
of CJD has been raised; however, this is rare and normally only occurs in cases where
a treatable condition is offered in the differential diagnosis. Examination of the brain
at autopsy is more common. Macroscopic analysis of the brain in vCJD cases is often
unremarkable, but some cerebral and cerebellar atrophy has been described in cases where
the disease duration extends over 19 months [137].
Histological and immunohistochemical examination has revealed a highly consistent
pattern of neuropathology in vCJD cases, very different to that of sCJD where there is
marked heterogeneity in terms of pathological phenotype [138]. Spongiform change is
a consistent feature in vCJD occurring in a widespread pattern throughout the cerebral
and cerebellar cortex, often found in a patchy distribution. The spongiform change is
generally most severe within the caudate nucleus and putamen in the basal ganglia. While
spongiform change is less prominent in the thalamus, severe neuronal loss and gliosis are
a consistent feature in the posterior nuclei, particularly the pulvinar. It is highly likely that
this pathology corresponds to the high signal observed on MRI in vCJD patients [131]. The
most striking pathological feature of vCJD is the presence of numerous “florid plaques”
within the cerebral and cerebellar cortex [137–139]. These plaques have the appearance of
the classic kuru-type plaques described in cases of kuru and sCJD MV2 cases, comprising
a dense eosinophilic amyloid core with radiating peripheral fibrils, but in cases of vCJD,
these plaques are often much larger and are surrounded by a halo of spongiform change
(Figure 4a) [138]. Florid plaques are rarely observed in other forms of human prion diseases,
although occasional florid plaques have been reported in cases of iatrogenic CJD associated
with dura mater grafting [140–142].
Figure 4. Pathological and biochemical features of vCJD. (a) A cluster of large rounded florid plaques present in the cerebral
cortex surrounded by a halo of mild spongiform change (Haematoxylin and Eosin stain). Original magnification; ×400
(b) Immunohistochemistry for the prion protein shows intense labelling of the florid plaques, and also demonstrates multiple
smaller cluster plaques (thick arrows) in addition to pericellular PrP deposits (thin arrows) in the frontal cortex. Original
magnification; ×200. (c) Peripheral pathology in vCJD demonstrating immunostaining for the prion protein in germinal
centres within the tonsil. Original magnification; ×200. (d) Representative Western blot analysis of post-mortem brain samples
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from a case of bovine spongiform encephalopathy in cattle and three individuals with vCJD. Western blot images are
compiled from individual Western blot analysis. The approximate positions of molecular mass markers are indicated
in kilodaltons.
Immunohistochemistry for PrP highlights a distinct and intense pattern of PrP accu-
mulation in the brain of vCJD cases [137,138]. In addition to the large florid plaques, smaller
plaque-like aggregates are identified by PrP immunohistochemistry, appearing in small
clusters throughout the cerebral cortex (Figure 4b). These plaque-like aggregates are rarely
visible through routine histological staining. In addition to plaques, small amorphous
‘feathery’ pericellular deposits of PrP are found surrounding the neurons or astrocytes
throughout the grey matter regions of the cerebral and cerebellar cortex. The basal ganglia
show a distinct PrP staining pattern in vCJD, comprising multiple small intense punctate
deposits occurring in a linear pattern of distribution [138].
5.3. Peripheral Pathology
Variant CJD differs from other forms of human prion disease in that there is widespread
and readily detectable accumulation of PrPSc in peripheral tissues of the body, primarily
associated with follicular dendritic cells within the follicles of lymphoid tissue (tonsil,
spleen, appendix, lymph nodes) (Figure 4c) [89,90]. Immunohistochemistry on archived
appendectomy samples from patients that went on to develop clinical vCJD, demonstrated
that PrPSc can accumulate in appendix tissue at least two years prior to the onset of clinical
symptoms [91]. Bioassay in wild-type mice has since confirmed infectivity associated with
PrPSc found within spleen and tonsil, but at levels around 100 to 1000 times lower than that
demonstrated in the brain [55]. More recently, the detection of infectivity and/or PrPSc in
the spleen of two suspected cases of asymptomatic vCJD compounded concerns over the
potential spread of vCJD by iatrogenic methods, particularly in regard to the use of surgical
instruments [56,99,108]. The significance of PrPSc accumulation within lymphoreticular
tissue in vCJD is demonstrated by the inclusion of a positive tonsil biopsy becoming part
of the diagnostic criteria for vCJD (Figure 3) [90,122].
In addition to lymphoreticular tissues, PrPSc has also been identified in a range of
tissues of the autonomic and peripheral nervous tissues (including; trigeminal, dorsal
root and autonomic ganglia) [143], peripheral motor nerve fibres in skeletal muscle [144],
pituitary gland [145], and in the dura mater, liver, pancreas, kidney, ovary, uterus and skin
in a single vCJD patient with a prolonged disease duration [146].
More recently, the use of the in vitro conversion assay PMCA in the detection of
minute quantities of PrPSc has suggested that the distribution of PrPSc in both clinical
and asymptomatic vCJD cases, and sCJD cases may be more widespread than initially
thought [147,148]. While PMCA is not currently included as a diagnostic tool for prion
diseases, recent studies have demonstrated that PMCA protocols offer sufficient sensitivity
and specificity for the amplification of minute amounts of PrPSc in biological fluids from
vCJD patients including, urine [149], blood [112,113,115] and CSF [150,151]. The detection
of PrPSc in blood was also demonstrated in blood samples taken at the presymptomatic
stage of vCJD [112]. No such detection of PrPSc in blood has been described with other hu-
man prion diseases, although PMCA has recently detected PrPSc in widespread peripheral
tissues of sCJD patients [148].
5.4. Biochemical Features
Biochemical analysis of frozen tissues (primarily CNS tissue) is a valuable addition in
the diagnosis of prion diseases. Western blot analysis of the protease-resistant fragments of
the prion protein from the brain of vCJD patients has identified a single PrPres type, termed
type 2B (also referred to as type 4 using the less commonly used London classification),
associated with vCJD-infected tissues [32,68]. This type 2B PrPres provides a “molecular
signature” for vCJD and is characterised by an unglycosylated fragment size of ~19kDa,
similar to that observed in sCJD type 2A cases but with a marked predominance in the
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diglycosylated fragment of PrPres (Figure 4d) [138]. PrPres detected within lymphoretricular
tissues in vCJD cases also show this type 2B biochemical phenotype. However, the non-
CNS tissues may show a further accentuation in the diglycosylated fragment and an
unglycosylated PrPres fragment that may be slightly smaller [89,90].
To date, PrPres type 2B has been identified in the brain of all clinical cases of primary
vCJD examined, regardless of the country of origin, or whether the codon 129 PRNP
genotype of the patient was MM or MV (Figure 4d) [71,75,84,152]. This same PrPres type
was also identified in the brain (Figure 4d) and tonsil from transfusion-associated secondary
vCJD [98,105] and in the spleen in two cases of asymptomatic vCJD infection [99,105]. This
distinctive PrPres type is rarely observed in other forms of human prion diseases.
6. Current Public Health Concerns from vCJD
Over the last decade, the numbers of cases of vCJD have declined [70,80]. While this
is reassuring, uncertainty surrounding possible future cases of vCJD continues to pose a
challenge for public health.
In the UK, concerns over a potential second wave of vCJD in individuals from different
PRNP codon 129 genotypes resurfaced in 2017, following the first report of pathologically
confirmed vCJD in a PRNP codon 129 MV patient (Figure 1) [84]. Until 2016, all definite
and probable cases of vCJD (with genetic testing) had occurred in PRNP codon 129 MM
individuals. The appearance of vCJD, the last case reported in the UK, in a PRNP codon
129 heterozygous individual, raised the possibility that further vCJD cases may appear in
this genotype, but they may be subject to extended incubation periods. This was supported
by earlier evidence from experimental transmission studies in humanised transgenic mice
(HuMM, HuMV and HuVV), which suggested that all three PRNP codon 129 genotypes
are susceptible to vCJD infectivity, but that each genotype is subject to differences in the
efficiency of transmission [53]. In this transmission study, extended incubation periods
were observed in HuMV mice compared to the HuMM mice, and, while clinical disease
was not observed in the HuVV mice, the appearance of neuropathology consistent with
a prion disease at autopsy indicated that PRNP codon 129 VV individuals may also be
susceptible to vCJD but after very long incubation times. It is worth noting that the animals
in this study, like the majority of animal modelling prion diseases, were challenged via
the intracerebral route of inoculation (IC). Whilst IC exposure represents a highly efficient
method of prion transmission in mice, results from this study may not provide a true
reflection of vCJD in humans resulting from oral exposure to BSE, or in cases of transfusion
transmitted secondary vCJD. However, similar reports of extended incubation periods in
PRNP codon 129 heterozygous individuals have been described in other acquired forms
of human prion disease involving oral and peripheral routes of exposure—specifically,
kuru [153] and human growth hormone associated iCJD cases in France [154]. This points
to the possibility of further cases of vCJD in this PRNP codon 129 genotype.
It is highly likely that UK residents were subject to a substantial dietary exposure
to the BSE agent during the 1980s and 1990s, with estimates suggesting that as many as
3 million asymptomatic BSE-infected animals entered the human food chain [12]. However,
as of June 2021, the number of clinical cases of vCJD in the UK remains relatively low
(n = 178) [80]. Such a discrepancy between the number of vCJD cases reported in the
UK and the number of people exposed to the BSE agent raises questions as to the extent
of asymptomatic vCJD infection in the UK population. The presence of asymptomatic
infection was demonstrated with the detection of PrPSc and/or infectivity in peripheral
tissues of vCJD patients during the long asymptomatic incubation periods [56,91] and
following reports of transfusion-transmission of vCJD infectivity from asymptomatic
donors who went onto develop vCJD [103].
The observation of PrPSc in vCJD lymphoreticular tissues, prior to the onset of clinical
symptoms, has been utilised in three UK retrospective studies aimed at estimating the
prevalence of PrPSc in the healthy UK population in order to assess the possible risks of fur-
ther secondary vCJD transmission via blood transfusion and potentially from other medical
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interventions. In the absence of a blood-based assay, and following the observation of PrPSc
in appendix tissue collected from vCJD patients prior to the onset of disease, analyses of
appendectomy (and some tonsilectomy) samples were selected for these studies (Figure 1).
The first study (Appendix-I study), reported in 2004, examined PrP immunohistochemical
analysis of anonymised appendectomy and tonsillectomy samples [155]. The samples
selected for this study had been resected from patients’ post-1995 to allow a greater chance
of PrP accumulation in the tissues following the potential exposure of these patients to BSE.
The individuals selected were all aged 20–29 years (birth cohort 1961–1985), which was
thought to represent the population at greatest risk of developing vCJD. Results confirmed
immunostaining consistent with PrPSc in 3/12,674 samples examined. All three positive
samples were found in appendix tissue. These results provided an estimated prevalence of
asymptomatic vCJD infection in the UK of 237 per million, or 1 in 4000 of the population,
with a wide confidence interval. A second and much larger study (Appendix-II study,
n = 32,441) examined appendectomy samples from a wider birth cohort (1940–1981). In this
study, 16 positive samples were identified, suggesting an even greater vCJD prevalence of
493 per million of the population, or 1 per 2000, again with a wide confidence interval [156].
Of additional concern from these two studies was the subsequent confirmation that the
positive appendix samples originated from patients of all three PRNP codon 129 geno-
types [156,157]. Importantly, this information supported the findings of animal studies that
have shown that all PRNP codon 129 genotypes are susceptible to vCJD infection but may
be subject to potentially lengthy incubation periods [53].
In view of the elevated prevalence rates indicated by Appendix studies-I and -II, a
third study was undertaken (Appendix-III study). In contrast to the previous two studies,
Appendix-III examined appendectomy samples from patients who were thought not be
exposed to the BSE agent—either having had their appendix removed prior to 1980 and the
BSE epidemic (“historical” cases), or having been born after 1996 and the implementation of
measures aimed at protecting the human food chain (“new” cases) [158,159]. The purpose
of the study was to “test the hypothesis that there would be an absence of samples positive
for abnormal PrP in appendices removed from people outside the population considered
most at-risk of acquiring vCJD from BSE” [159]. Preliminary results were published by
Public Health England in 2016, in which they reported 7/29,516 appendix samples positive
for the prion protein [158]. Two of the positive samples originated from the historical
cohort of appendices, with the other five originating from the new cohort. The complete
data set was published in March 2020 and confirmed a statistically similar prevalence rate
to that reported in Appendix-II study [159]. The demonstration of PrP in the appendices
collected from individuals thought to have had no exposure to the BSE agent, is difficult
to interpret. However, the authors of the study suggest that dietary exposure in the UK
population to the BSE agent may have occurred over a more extended time period that
initially thought, or that there may be a low prevalence of abnormal PrP in lymphoreticular
tissues that does not progress to vCJD.
7. Concluding Remarks
Twenty-five years has now passed since the first description of vCJD in the UK.
Reassuringly, case numbers in the UK and worldwide remain relatively low with 232
clinical cases of definite or probable vCJD reported to date. Furthermore, following the
implementation of rigorous control measures aimed at ensuring food safety, the risk of
further dietary exposure of the population to the BSE agent has been almost entirely
eliminated. However, as we move forward, uncertainty remains over the potential for
future vCJD cases and the enduring implications for public health. The recent emergence
of vCJD in a MV heterozygote has raised questions regarding the possibility of a second
wave of vCJD in individuals from other codon 129 PRNP genotypes (codon 129 MV and
VV individuals), perhaps following lengthy incubation periods. Possible changes in the
clinical presentation of vCJD in PRNP codon 129 MV and VV individuals is uncertain but
could impede the identification of further vCJD cases. Furthermore, it is possible that cases
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of vCJD that occur in older individuals (>65 years) may not be recognised, particularly
because other neurodegenerative conditions with similar clinical presentation are relatively
common in this age group. Certainly, the current decline observed in the rate of UK hospital
autopsies is of great concern in this regard [160].
Following confirmation that vCJD infectivity can be transmitted from human-to-
human via transfusion with blood products collected from asymptomatic individuals, the
potential for a self-sustained epidemic by blood transfusion is an ongoing public health
consideration. Such concerns are exacerbated by the absence of a reliable and rapid blood
assay for vCJD. While there is currently no evidence of transmission of vCJD through
other medical interventions such as surgery, the potential for such cases to arise cannot be
discounted. With such unanswered questions remaining, and the implications for public
health, the continuation of surveillance for vCJD and other forms of human prion disease
is imperative.
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